(Q40970585)

25 September 2017

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients (English)

1 reference

25 September 2017

1 reference

Zackheim HS

1

1 reference

25 September 2017

Kashani-Sabet M

series ordinal

2

1 reference

25 September 2017

Hwang ST

series ordinal

3

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 April 1996

1 reference

Journal of the American Academy of Dermatology

25 September 2017

1 reference

25 September 2017

34

1 reference

25 September 2017

4

1 reference

25 September 2017

626-631

1 reference

Sézary syndrome: diagnosis, prognosis, and critical review of treatment options

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Subcutaneous administration of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Methotrexate in psoriasis: revised guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Guidelines for reporting outcomes of lymphoma trials

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Reporting outcomes in Hodgkin's disease and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Thymopentin in Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Why does a higher response rate to chemotherapy correlate poorly with improved survival?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2980062-4

7 January 2021

10.1016/S0190-9622(96)80062-4

Identifiers

DOI

1 reference

25 September 2017

1 reference